Corporate Profile
LianBio (NASDAQ: LIAN) is a cross-border biotechnology company on a mission to bring transformative medicines to historically underserved patients in Greater China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing a diversified portfolio of product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. LianBio’s model leverages a number of key elements, including transformative in-licensing, development and commercialization approaches designed to deliver innovative therapeutic solutions to patients. LianBio is establishing an international infrastructure to position the company as a partner of choice with a platform to provide access to China and other Asian markets.
Stock Quote
Price
Change
High
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
December 19, 2022
December 13, 2022
November 10, 2022
Events & Presentations
November 16, 2022 at 10:55 AM UTC
June 15, 2022 at 2:40 PM PDT
June 10, 2022 at 11:00 AM EDT
Contact
Elizabeth Anderson
Elizabeth.anderson@lianbio.com
IR@lianbio.com